The role of the gut microbiome in mood disorders is an emerging, fascinating field in neuroscience and medicine. Numerous studies have shown that the gut microbiota (colonies of both “good” and “bad” bacteria living in [...]
Dr. Lee S. Cohen recently shared news of a new screening application for postpartum depression with ObGyn News
According to a study published last year in the journal Pediatrics, adolescent depression is on the rise. In adolescents, the 12-month prevalence of major depression increased from 8.7% in 2005 to 11.3% in 2014. Other [...]
It is fairly well-known that interactions between parents and children are associated with improved developmental outcomes in children. Previous research has primarily focused on how maternal rather than paternal involvement influences infant neurodevelopment. A recent [...]
We know that about 15% of women suffer from postpartum depression (PPD). But what is less clear is how to reliably identify women with PPD and to then ensure that they get the support and [...]
About 1.4 million people in the U.S. have been diagnosed with ADHD, and about 60-80% of children diagnosed with ADHD will need to take their medication into adulthood. When girls diagnosed in childhood become [...]
We are very pleased to announce the release of the MGH Perinatal Depression Scale available free of charge on the App Store (https://appsto.re/us/-3X4jb.i). The MGHPDS smartphone app includes digital versions of perinatal depression screening tools [...]
It is estimated that suicide accounts for about 10% of all maternal deaths. While we have a fair amount of information to help us predict which women are at risk for depression during pregnancy and [...]
Over the last decade, there has been increased interest around the country in establishing consistent screening for perinatal depression across a range of clinical settings. Approximately 40 states have instituted guidelines and recommendations regarding screening [...]
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of severe postpartum depression. SAGE-547, now called brexanolone, is a new type of antidepressant: a formulation of allopregnanolone, which is [...]
